Respiratory Syncytial Virus

Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

American Society of Consultant Pharmacists executive director and CEO explained how staffing struggles in long-term care facilities can be an opportunity for pharmacists to expand the ways they provide support beyond immunizations alone.

Infection with RSV can take a variety of forms, ranging from a mild upper respiratory tract infection to severe, life-threatening acute respiratory failure.

Pre-planned safety reviews performed for the duration of the study found that the investigational vaccine is well-tolerated with no safety concerns for both the vaccinated individuals and their newborns.

Researchers suggest that winter 2020 to 2021 public health interventions lowered natural immunity in children and put them at greater risk of respiratory infection after restrictions were lifted.

There is currently no approved RSV vaccine despite ongoing research efforts.

The TaqMan SARS-CoV-2, Flu A/B, RSV RT-PCR multiplex assay can differentiate between 3 different viral infections (including COVID-19), making it highly cost-effective.

The vaccine candidate is composed of 2 preF proteins selected to optimize protection against the RSV A and B strains.

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, discussed how mRNA vaccines could change the treatment landscape for respiratory illnesses.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

This month's Rx product news features empagliflozin, mitapivat, and RSVpreF.

The Labcorp Seasonal Respiratory Virus RT-PCR DTC Test is the first direct-to-consumer multi-analyte COVID-19 test to be authorized by FDA.

RSVpreF gets breakthrough designation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age or older.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

RSV causes an estimated 14,000 deaths and 177,000 hospitalizations annually among US adults over 65 years of age.

The study aimed to examine the impact of masking and social distancing practices used to control the spread of COVID-19.

Samples for the test are isolated from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs.

RSV is defined as a seasonal illness that starts in the fall months and peaks during the winter when other respiratory illnesses are more common.

Testing for respiratory syncytial virus (RSV) infection during the influenza season is uncommon among pregnant mothers.